Bayer wins Japan nod for finerenone in broad heart failure population
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
Full approval will depend on verification of clinical benefit in a confirmatory trial
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Subscribe To Our Newsletter & Stay Updated